A Blueprint For Sustained Trauma-Informed Care: The Hillsides & Klingberg Family Centers Case Study is starting in

The consumer outcome benefits of medication-assisted addiction treatment (MAT) for addictions are well documented, including higher remission (see Real-World Effectiveness Of Medication-Assisted Treatment And Psychotherapy For Opioid Use Disorder), increased odds of survival (see Evaluating The Optimal Duration Of Medication Treatment For Opioid Use Disorder), and fewer days of illicit opioid use (see Emergency Department–Initiated Buprenorphine For Opioid Use Disorder).

And the cost offset for these therapies is also well researched. A recent study—Association Between Extended-Release Buprenorphine Adherence And Reduced Healthcare Costs Among Insured Patients With Opioid Use Disorder—added to that research base. The study examined commercially insured and Medicare consumers with opioid use disorder